-
公开(公告)号:EP3438094A1
公开(公告)日:2019-02-06
申请号:EP17773212.0
申请日:2017-03-28
发明人: LIU, Qingsong , LIU, Jing , WANG, Qiang , WANG, Beilei , LIU, Feiyang , QI, Shuang , QI, Ziping , ZOU, Fengming , CHEN, Cheng , WANG, Wenchao , HU, Chen , LIU, Xiaochuan , WANG, Wei , WANG, Aoli , WANG, Li , HU, Zhenquan , REN, Tao
IPC分类号: C07D211/44 , C07D401/04 , C07D413/04 , C07D413/14 , C07D401/14 , C07D409/14 , A61K31/45 , A61K31/4545 , A61K31/454 , A61P35/00 , A61P35/02
摘要: The present invention provides a compound represented by formula (I), or a pharmaceutically acceptable salt, a solvate, an ester, an acid, a metabolite or a prodrug thereof. The compound itself in the present invention or in combination with at least one therapeutic agent can be used for preventing or treating diseases, disorders or symptoms caused by the adjustment of the activity of tyrosine kinase C-KIT, or affected by the activity of the tyrosine kinase C-KIT or involving in the activity of the tyrosine kinase C-KIT, especially cancers or other cell proliferation diseases.
-
公开(公告)号:EP3392245A1
公开(公告)日:2018-10-24
申请号:EP16874860.6
申请日:2016-12-15
发明人: LIU, Jing , LIU, Qingsong , JIANG, Taoshan , WANG, Aoli , WU, Jiaxin , WU, Hong , QI, Ziping , CHEN, Yongfei , ZOU, Fengming , WANG, Wenchao , ZHAO, Zheng , WANG, Li , WANG, Beilei
IPC分类号: C07D401/12 , C07D239/48 , C07D403/12 , C07D239/47 , C07D409/12 , A61K31/506 , A61K31/5377 , A61K31/551 , A61P35/00 , A61P35/02
CPC分类号: A61K31/506 , A61K31/5377 , A61K31/551 , C07D239/47 , C07D239/48 , C07D401/12 , C07D403/12 , C07D409/12 , Y02P20/55
摘要: The present application provides a compound of formula I, which is a EGFR and ALK dual inhibitor and can be used alone or in combination with other therapeutic agents to treat diseases such as non-small cell lung cancer. The compounds of the present application are useful in the treatment of diseases carrying the EGFR wild-type gene, or carrying the EGFR T790M mutant gene and/or the EGFR L858R mutant gene and/or the EGFR delE746_A750 mutant gene, or in the treatment of diseases carrying the ALK wild-type gene, ALK F1174L mutant gene and/or ALK F1196M gene and/or EML4-ALK mutant gene and/or NPM-ALK mutant gene, and can be used in the first-line treatment of anaplastic lymphoma kinase (ALK) positive late-stage non-small cell Lung cancer.
-